McKechnie Mark

McKechnie Mark sold 98,551 shares at $44.89–$46.57 on 2026-03-12 for $4,491,951.58, reducing stake by 99.1%.

Mark McKechnie executed six separate sales totaling 98,551 shares for $4,491,951.58 at prices ranging from $44.89 to $46.57, leaving only 900 shares post-transaction. This represents a near-complete exit from his ACMR position, with the blended average price of $45.58 occurring 30 days and 90 days into declines of -34.4% each relative to the 52-week high of $70.68. His prior sales at this ticker (December 2025) generated positive 90-day returns of 26.7%, 54.7%, and 51.3%, indicating those earlier exits were poorly timed relative to subsequent stock appreciation. The current transaction executed near the top of the 52-week range ($46.38 current vs $70.68 peak) on a stock posting strong fundamentals—$269.2M revenue, $35.9M net income, 15.2% annual growth, and a 6.11 P/E ratio. The scale and execution pattern merit observation given the insider's history at this ticker and the company's valuation context.

McKechnie Mark sold 31,250 shares (97.2% of holdings) across 3 transactions for $1,091,506.96 at ACMR; 900 shares remain.

McKechnie Mark executed 3 separate sales totaling 31,250 shares for $1,091,506.96 between December 4–8, 2025, at prices ranging from $33.50 to $35.45 (blended average $34.93), reducing his holdings from 32,150 shares to 900 shares—a -97.2% reduction. The stock currently trades at $36.54, up 17.5% over 30 days and 30.9% over 90 days, and carries strong fundamentals: annual revenue growth of +40.2%, P/E of 4.42, and net income of $35.9M on revenue of $269.2M. The near-total liquidation of a position by a named executive represents a material change in insider alignment with the company, occurring against a backdrop of recent strong momentum and low valuation multiples relative to growth.